IC
BCYC

Ikarian Capital’s Bicycle Therapeutics BCYC Stock Holding History

Ikarian Capital’s Portfolio BCYC Stock Details BCYC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-106,600
Closed -$4.68M – 151
2022
Q1 		$4.68M Buy
+106,600
New +$4.98M 0.62% 44

Other funds holding BCYC

PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return
JFG
Jefferies Financial Group New York $14.6B AUM 40.95% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
TCM
Tybourne Capital Management Hong Kong $30.9M AUM 20.1% 1-Year Est. Return
CS
Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return

Ikarian Capital's BCYC Position: Q3 2023 in Review

Ikarian Capital sold out of Bicycle Therapeutics (BCYC) in Q3 2023, closing a stake of 203,037 shares — an estimated $5.18M sold.

Ikarian Capital first reported a position in BCYC in Q3 2021 and held it in 5 quarters. The position peaked at $37.3M in Q4 2021. 101 funds tracked by Wall St. Rank hold BCYC as of Q3 2023.

  • Ikarian Capital reported no remaining Bicycle Therapeutics position as of Q3 2023 after selling out during the quarter.
  • Ikarian Capital sold 203,037 Bicycle Therapeutics shares in Q3 2023, an estimated $5.18M.
  • Ikarian Capital first reported a position in Bicycle Therapeutics in Q3 2021 and held it in 5 quarters.
  • Ikarian Capital's Bicycle Therapeutics position peaked at $37.3M in Q4 2021.
  • 101 funds tracked by Wall St. Rank held Bicycle Therapeutics as of Q3 2023.

Based on Ikarian Capital's 13F filing for Q3 2023, filed 14 Nov 2023.